[Analysis of liver histological characteristics and clinically related factors in patients with inactive HBsAg carriers].
<b>Objective:</b> To analyze the liver histological characteristics and clinically related factors in inactive hepatitis B surface antigen (HBsAg) carriers (IHC), and also explore whether antiviral treatment is necessary for IHC, as defined in the 2022 version of the hepatitis B prevention and treatment guidelines. <b>Methods:</b> A multicenter, retrospective cohort study was conducted. Two hundred and thirty-one IHC cases who underwent liver biopsy histopathological examination in nine medical institutions, including Beijing Youan Hospital affiliated with Capital Medical University, from January 2018 to December 2023 were included. General informative data, clinical serological markers, and transient elastography (TE) examination results were collected. Patients were divided into a positive (148 cases) and a negative group (83 cases) according to the results of hepatitis B virus (HBV) DNA detection. The differences in liver pathological inflammatory activity (G) and liver fibrosis stage (S) were analyzed between the two groups to explore the correlation between liver tissue conditions and clinically related factors. Comparsions of normally distributed continwous data, skeukd continuous data, and categorical data between groups are performed using <i>t</i> tests, Mann-Whitney <i>U</i> tests and <i></i><sup>2</sup> tests, respectively. <b>Results:</b> The age of 231 IHC cases was 43 (38, 51) years old, with 95.2% (220/231) aged ≥30 years, and males accounted for 64.9% (150/231). HBsAg and HBV DNA levels were 131.9 (20.8, 400.9) IU/mL and 94.0 (0, 448.5) IU/mL, respectively, of which 35.9% (83/231) were HBV DNA negative (<20 IU/mL). The remarkable proportions of G≥2, S≥2, and liver injury (G≥2 and/or S≥2) in liver tissue were 16.5% (38/231), 29% (67/231), and 35.9% (83/231), respectively. The S≥2 proportion was significantly higher in the HBV DNA-negative group than the positive group (42.2% <i>vs</i>. 21.6%, <i>P</i><0.001), and it mainly occurred in the population cohort over 30 years old (44.9% <i>vs</i>. 31.0%, <i>P</i>=0.04). The liver stiffness measurement (LSM), aspartate transaminase to platelet ratio index (APRI), and platelet (PLT) were significantly higher in the S≥2 group than the S<2 group (<i>P</i><0.05). <b>Conclusion:</b> Clinicians can comprehensively evaluate the degree of liver fibrosis in IHC based on clinical factors such as age, PLT, APRI, and LSM, even if the liver histological results are lacking. The China 2022 version guidelines define that nearly half of IHC has histological indications for antiviral therapy, and liver biopsy and prompt treatment can be recommended.
Authors
- Hua Gao (ORCID: https://orcid.org/0000-0002-1326-6946)
- Yanchen Xie (ORCID: https://orcid.org/0000-0002-7879-0554)
- Fan Yang (ORCID: https://orcid.org/0000-0002-9805-9099)
- Junliang Fu (ORCID: https://orcid.org/0009-0001-8318-6888)
- Ruirui Fan
- X Y Chen (ORCID: https://orcid.org/0009-0001-8407-8774)
- M H Li (ORCID: https://orcid.org/0000-0001-6327-9983)
- Sujun Zheng (ORCID: https://orcid.org/0000-0002-6367-5764)
- Qiang Ruan (ORCID: https://orcid.org/0000-0002-6138-4357)
- Wen Huang (ORCID: https://orcid.org/0000-0002-9772-9492)
- Shan Ren (ORCID: https://orcid.org/0000-0002-5279-6464)
- X Y Zhang (ORCID: https://orcid.org/0009-0001-0768-8034)
- Xiaolin Xue
Institutions
- Fujian Medical University (CN)
- Chinese PLA General Hospital (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Integrated Chinese Medicine (China) (HK)
- Mengchao Hepatobiliary Hospital (CN)
- Beijing YouAn Hospital (CN)
- Beijing Ditan Hospital (CN)
- Xiamen Chang Gung Hospital (CN)
- The Sixth People's Hospital of Shenyang (CN)
- Shenzhen Pingle Orthopedic Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-07-20
- DOI
- https://doi.org/10.3760/cma.j.cn501113-20241115-00580
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Municipal Health Commission
- National Key Research and Development Program of China